Adage Capital Partners Gp, L.L.C. Gilead Sciences, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

$54.6 Billion
Q3 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$71.58 - $87.29 $7.26 Million - $8.85 Million	101,387 New	101,387 $7.43 Million
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $29.3 Million - $33.4 Million	-385,596 Reduced 23.62%	1,246,588 $96.1 Million
Q1 2023 May 15, 2023	BUY	$77.31 - $88.08 $5.84 Million - $6.65 Million	75,500 Added 4.85%	1,632,184 $135 Million
Q4 2022 Feb 14, 2023	BUY	$62.32 - $89.47 $36.5 Million - $52.4 Million	585,707 Added 60.32%	1,556,684 $134 Million
Q3 2022 Nov 14, 2022	SELL	$59.54 - $68.01 $7.1 Million - $8.11 Million	-119,300 Reduced 10.94%	970,977 $59.9 Million
Q2 2022 Aug 15, 2022	BUY	$57.72 - $65.01 $51.8 Million - $58.4 Million	898,300 Added 467.92%	1,090,277 $67.4 Million
Q1 2022 May 16, 2022	SELL	$57.92 - $72.58 $47.4 Million - $59.4 Million	-818,800 Reduced 81.01%	191,977 $11.4 Million
Q4 2021 Feb 14, 2022	BUY	$64.88 - $73.64 $62.4 Million - $70.8 Million	961,300 Added 1942.92%	1,010,777 $73.4 Million
Q3 2021 Nov 15, 2021	SELL	$67.69 - $73.03 $38.5 Million - $41.6 Million	-569,300 Reduced 92.0%	49,477 $3.46 Million
Q2 2021 Aug 16, 2021	BUY	$63.47 - $69.35 $35.3 Million - $38.6 Million	556,200 Added 888.82%	618,777 $42.6 Million
Q1 2021 May 17, 2021	SELL	$60.0 - $68.46 $84,000 - $95,843	-1,400 Reduced 2.19%	62,577 $4.04 Million
Q4 2020 Feb 16, 2021	SELL	$56.65 - $64.55 $13.1 Million - $14.9 Million	-231,000 Reduced 78.31%	63,977 $3.73 Million
Q3 2020 Nov 16, 2020	BUY	$62.1 - $78.08 $18.3 Million - $23 Million	294,977 New	294,977 $18.6 Million
Q2 2020 Aug 14, 2020	SELL	$72.34 - $84.0 $80.5 Million - $93.4 Million	-1,112,325 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$62.63 - $80.22 $9.46 Million - $12.1 Million	-151,100 Reduced 11.96%	1,112,325 $83.2 Million
Q4 2019 Feb 14, 2020	SELL	$61.62 - $67.78 $4.81 Million - $5.29 Million	-78,000 Reduced 5.81%	1,263,425 $82.1 Million
Q3 2019 Nov 14, 2019	SELL	$62.51 - $69.0 $887,642 - $979,800	-14,200 Reduced 1.05%	1,341,425 $85 Million
Q2 2019 Aug 14, 2019	BUY	$61.87 - $69.38 $5.02 Million - $5.63 Million	81,100 Added 6.36%	1,355,625 $91.6 Million
Q1 2019 May 15, 2019	SELL	$62.53 - $70.05 $18.9 Million - $21.2 Million	-302,700 Reduced 19.19%	1,274,525 $82.9 Million
Q4 2018 Feb 14, 2019	BUY	$60.54 - $79.0 $3.13 Million - $4.09 Million	51,731 Added 3.39%	1,577,225 $98.7 Million
Q3 2018 Nov 14, 2018	SELL	$71.28 - $78.92 $6.6 Million - $7.31 Million	-92,600 Reduced 5.72%	1,525,494 $118 Million
Q2 2018 Aug 14, 2018	SELL	$64.88 - $75.68 $8.95 Million - $10.4 Million	-137,896 Reduced 7.85%	1,618,094 $115 Million
Q1 2018 May 15, 2018	BUY	$72.84 - $88.8 $21.3 Million - $26 Million	292,330 Added 19.97%	1,755,990 $132 Million
Q4 2017 Feb 14, 2018	SELL	$71.15 - $83.52 $11.8 Million - $13.8 Million	-165,600 Reduced 10.16%	1,463,660 $105 Million
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $117 Million - $139 Million	1,629,260	1,629,260 $132 Million

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

Black Rock Inc. New York, NY

121M
Shares

$11.2 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.7 Billion
0.18% of portfolio
Capital World Investors Los Angeles, CA

76.5M
Shares

$7.09 Billion
1.03% of portfolio
Capital Research Global Investors Los Angeles, CA

61.8M
Shares

$5.72 Billion
1.12% of portfolio
State Street Corp Boston, MA

60.2M
Shares

$5.57 Billion
0.21% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.

Account